Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

What this Trial Is About

Researchers are evaluating a new way to provide genetic testing information to patients with cancer, comparing a computer-generated conversational agent called PERLA to usual care involving a human genetics healthcare provider. The study focuses on patients who may have limited access to genetic counseling, especially those from racial or ethnic minority groups and rural areas served by safety-net hospitals. The study aims to improve access to genetic testing, which is becoming standard care for many cancer patients, by using health information technology to offer education in both English and Spanish. The study includes several phases: development, usability testing, pilot testing, and an intervention phase. In the intervention phase, patients are randomly assigned to one of two groups. One group receives pre-test genetics education through PERLA followed by standard post-test counseling by a provider, while the other group receives usual care with both pre- and post-test counseling from a provider. The education sessions last between 20 and 60 minutes. After the intervention, participants complete interviews to identify barriers and facilitators to implementing PERLA in clinical settings. Participants attend focus groups, usability tests, and interviews throughout the study to provide feedback on PERLA's content and usability. They are followed up at 1, 3, and 6 months after the intervention. Researchers measure the proportion of patients who receive genetic test results within 3 months of starting cancer care and collect patient-reported outcomes during this period. The study also includes ancillary activities such as surveys, interviews, and electronic health record reviews to support the research goals.

Access to Genetic Testing in Underserved Patients With Cancer